COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,846 Articles (22,553 medRxiv, 8,293 bioRxiv)

Most recent first Previous |  Page 1079: Articles 10781-10790  | Next

An integrative method for COVID-19 patients classification from chest X-ray using deep learning network with image visibility graph as feature extractor
Pal, M., Tiwari, Y., Reddy, T. V., Parisineni, S. R. A., Panigrahi, P. K.
10.1101/2021.11.17.21266472 — Posted: 2021-11-21
COVID-19 testing systems and their effectiveness in small, semi-isolated groups for sports events
Kamo, M., Murakamo, M., Naito, W., Takeshita, J.-i., Yasutaka, T., Imoto, S.
10.1101/2021.11.18.21266507 — Posted: 2021-11-21
Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course
Pillay, J., Bialy, L., Gaudet, L., Wingert, A., Mackie, A., Paterson, D. I., Hartling, L.
10.1101/2021.11.19.21266605 — Posted: 2021-11-21
Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine
Wanlapakorn, N., Yorsaeng, R., Phowatthanasathian, H., Suntronwong, N., Kanokudom, S., Sudhinaraset, N., Poovorawan, Y.
10.1101/2021.11.20.21266644 — Posted: 2021-11-21
Comprehensive genomic, immunological and clinical analysis of COVID-19 vaccine breakthrough infections: a prospective, comparative cohort study
Tian, D., Song, Y., Zhang, M., Pan, Y., Ge, Z., Zhang, Y., Ren, X., Wen, J., Xu, Y., Guo, H., Yang, P., Chen, Z., Xu, W.
10.1101/2021.11.17.21266499 — Posted: 2021-11-21
Longitudinal analysis of antibody trajectories and humoral responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy (RituxiVac 2.0)
Sidler, D., Born, A., Schietzel, S., Horn, M. P., Aeberli, D., Amsler, J., Moeller, B., Njue, L. M., Medri, C., Angelillo-Scherrer, A., Borradori, L., Seyed Jafari, S. M., Radonjic-Hoesli, S., Chan, A., Hoepner, R., Bacher, U., Mani, L.-Y., Iype, J. M., Suter-Riniker, F., Staehelin, C., Nagler, M., Hirzel, C., Maurer, B., Moor, M. B.
10.1101/2021.11.19.21266572 — Posted: 2021-11-21
How many relevant SARS-CoV-2 variants might we expect in the future?
Littera, R., Melis, M.
10.1101/2021.11.17.21266463 — Posted: 2021-11-21 Discussion: Onsite
Limited immune responses after three months of BNT162b2 vaccine in SARS-CoV-2 uninfected elders living in long-term care facilities
Trigueros, M., Pradenas, E., Palacin, D., Avila-Nieto, C., Trinite, B., Bonet-Simo, J. M., Isnard, M., Moreno, N., Marfil, S., Rovirosa, C., Puig, T., Grau, E., Chamorro, A., Martinez, A., Toledo, R., Font, M., Ara, J., Carrillo, J., Mateu, L., Blanco, J., Clotet, B., Prat, N., Massanella, M.
10.1101/2021.11.18.21266502 — Posted: 2021-11-21
Transmission of B.1.617.2 Delta Variant between vaccinated healthcare workers in Delhi, India
Kemp, S. A., Cheng, M. T., Hamilton, W., Kamelian, K., INSACOG Consortium, , Singh, S., Rakshit, P., Aggrawal, A., Illingworth, C., Gupta, R. K.
10.1101/2021.11.19.21266406 — Posted: 2021-11-21
Longitudinal SARS-CoV-2 RNA Wastewater Monitoring Across a Range of Scales Correlates with Total and Regional COVID-19 Burden in a Well-Defined Urban Population
Acosta, N., Bautista, M., Waddell, B. J., McCalder, J., Buchner Beaudet, A., Man, L., Pradhan, P., Sedaghat, N., Papparis, C., Bacanu, A., Hollman, J., Krusina, A., Southern, D., Williamson, T., Li, C., Bhatnagar, S., Murphy, S., Chen, J., Kuzma, D., Meddings, J., Hu, J., Cabaj, J., Conly, J., Ruecker, N., Achari, G., Ryan, C. M., Frankowski, K., Hubert, C., Parkins, M.
10.1101/2021.11.19.21266588 — Posted: 2021-11-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).